Your browser doesn't support javascript.
loading
Sulforaphane Diminishes the Formation of Mammary Tumors in Rats Exposed to 17ß-Estradiol.
Palliyaguru, Dushani L; Yang, Li; Chartoumpekis, Dionysios V; Wendell, Stacy G; Fazzari, Marco; Skoko, John J; Liao, Yong; Oesterreich, Steffi; Michalopoulos, George K; Kensler, Thomas W.
Afiliação
  • Palliyaguru DL; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
  • Yang L; Translational Gerontology Branch, National Institute on Aging, Baltimore, MD 21224, USA.
  • Chartoumpekis DV; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
  • Wendell SG; Department of Toxic Substances Control, California Environmental Protection Agency, Cypress, CA 90630, USA.
  • Fazzari M; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
  • Skoko JJ; Department of Internal Medicine, Division of Endocrinology, University of Patras, 26504 Patras, Greece.
  • Liao Y; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
  • Oesterreich S; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
  • Michalopoulos GK; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
  • Kensler TW; Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Nutrients ; 12(8)2020 Jul 30.
Article em En | MEDLINE | ID: mdl-32751496
Elevated levels of estrogen are a risk factor for breast cancer. In addition to inducing DNA damage, estrogens can enhance cell proliferation as well as modulate fatty acid metabolism that collectively contributes to mammary tumorigenesis. Sulforaphane (SFN) is an isothiocyanate derived from broccoli that is currently under evaluation in multiple clinical trials for prevention of several diseases, including cancer. Previous studies showed that SFN suppressed DNA damage and lipogenesis pathways. Therefore, we hypothesized that administering SFN to animals that are co-exposed to 17ß-estradiol (E2) would prevent mammary tumor formation. In our study, 4-6 week old female August Copenhagen Irish rats were implanted with slow-release E2 pellets (3 mg x 3 times) and gavaged 3x/week with either vehicle or 100 µmol/kg SFN for 56 weeks. SFN-treated rats were protected significantly against mammary tumor formation compared to vehicle controls. Mammary glands of SFN-treated rats showed decreased DNA damage while serum free fatty acids and triglyceride species were 1.5 to 2-fold lower in SFN-treated rats. Further characterization also showed that SFN diminished expression of enzymes involved in mammary gland lipogenesis. This study indicated that SFN protects against breast cancer development through multiple potential mechanisms in a clinically relevant hormonal carcinogenesis model.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Mamárias Animais / Anticarcinógenos / Isotiocianatos / Neoplasias Mamárias Experimentais Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Mamárias Animais / Anticarcinógenos / Isotiocianatos / Neoplasias Mamárias Experimentais Idioma: En Ano de publicação: 2020 Tipo de documento: Article